<DOC>
	<DOCNO>NCT00048373</DOCNO>
	<brief_summary>The purpose study learn response Langerhans cell histiocytosis ( LCH ) Enbrel patient fail respond standard therapy . We also look specifically side effect Enbrel patient . We expect enroll 20 patient study anticipate subject active participation last one year .</brief_summary>
	<brief_title>Treatment Resistant Langerhans Cell Histiocytosis With ENBREL</brief_title>
	<detailed_description>After subject complete pretreatment evaluation , receive injection Enbrel - study drug - ( give skin ) twice weekly . If subject disease stabilizes regress , may continue receive treatment 1 year . Subjects disease involvement risk organ ( mean patient disease liver , lung , spleen , bone marrow ) : admit hospital observation first week administration Enbrel . If first two dos appear problem , subject may follow outpatient twice weekly evaluation visit ( similar perform treatment begin ) abnormal blood test become normal . Then frequency clinic visit decrease similar describe subject without disease involvement risk organ . Subjects without disease involvement risk organ treat outpatient . While receive treatment , subject may receive chemotherapy agent . Doctors monitor subject closely side effect . Most side effect usually disappear treatment stop . In meantime , however , doctor may prescribe medication keep side effect control .</detailed_description>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>INCLUSION : Age : Patients age great 1 year 65 year age . An internal medicine boardcertified physician also evaluate adult patient . Histologic diagnosis : Patients must histologically confirm LCH refractory standard therapy . Recovery prior therapy : Patients must recover toxic effect prior therapy may abnormal hematologic , hepatic , lab value secondary disease . Life expectancy : Patients must life expectancy least 8 week . Performance status : Patients must Lansky performance status great 40 Karnofsky status great 40 . Informed consent : All patient legal guardian ( patient &lt; 18 year age ) must sign document inform consent indicate awareness investigational nature risk study . When appropriate patient include discussion order obtain verbal consent . Hematologic status : Patients hematologic status may enrol since resistant LCH may require considerable transfusion support . Durable Power Attorney ( DPA ) : A DPA must offer patient 18 year age old . EXCLUSION : Women childbearing potential pregnant lactating exclude . Patients active infection must treat prior entry . Significant disease investigator feel complicate review/evaluation study data ( example : uncontrolled diabetes , multiple sclerosis ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>LANGERHANS</keyword>
	<keyword>HISTIOCYTOSIS</keyword>
</DOC>